We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Type
Editorials: Perspectives on the Romanow Commission Report/Éditoriaux : Perspectives sur le Rapport de la Commission Romanow
1Commission sur l'avenir des soins de santé au Canada. Guidé par nos valeurs: l'avenir des soins de santé au Canada—rapport final. Ottawa: Gouvernement du Canada; 2002.Google Scholar
2
2Taylor, MG. Health insurance and Canadian public policy: the seven decisions that created the Canadian health insurance system and their outcomes. 2e éd. Montréal: McGill-Queen's University Press; 1987.Google Scholar
3
3Millar, WJ. Disparités des régimes d'assurance-médicaments. Rapports sur la santé1999;10:11–21.Google Scholar
4
4Institut canadien d'information sur la santé. Drug expenditure in Canada, 1985–2001. Ottawa: Institut canadien d'information sur la santé; 2002.Google Scholar
5
5Willison, D, Grootendorst, P, Hurley, J. Variation in pharmacare coverage across Canada. Document de travail 9808 du McMaster Centre for Health Economics and Policy Analysis Research; septembre 1998.Google Scholar
6
6Menec, VH, MacWilliam, L, Sooden, RA et Mitchell, L. (2002). The health and health care use of Manitoba's seniors: have they changed over time?Winnipeg, MB: Centre d'élaboration et d'évaluation de la politique des soins de santé au Manitoba.Google Scholar
7
7Soumerai, SB, Ross-Degnan, D, Avorn, J, McLaughlin, T, Choodnovskiy, I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med1991;325:1072–7.Google Scholar
8
8Tamblyn, R, Laprise, R, Hamley, JA, Abrahamowicz, M, Scott, S, Mayo, N, et al. . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA2001;285:421–9.Google Scholar
9
9Cox, ER, Henderson, RR. Prescription use behaviour among medicare beneficiaries with capped prescription benefits. J Managed Care Pharmacy2002;8:360–4.CrossRefGoogle ScholarPubMed
10
10Kozyrskyj, AL, Morgan, S, Dahl, M. Manitoba prescription cost data: an analysis for the Romanow Commission (données non publiées). Winnipeg, MB; September 2002.Google Scholar
11
11Willcox, SMM, Himmelstein, DU, Woolhandler, D. Inappropriate drug prescribing for the community-dwelling elderly. JAMA1994;272: 292–6.CrossRefGoogle ScholarPubMed
12
12Tamblyn, RM, McLeod, PJ, Abrahamowicz, M, Monette, J, Gayton, DC, Berkson, L, et al. . Questionable prescribing for elderly patients in Quebec. CMAJ1994; 150: 1801–9.Google Scholar
13
13Mannesse, CK, Derkx, FHM, de Ridder, MAJ, Veld, AJM, van der Cammen, TJM. Contribution of adverse drug reactions to hospital admissions of older patients. Age Ageing2000;29:35–9.Google Scholar
14
14Lipton, HL, Bero, LA, Bird, JA, McPhee, SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing: a randomized controlled trial. Med Care1992;30:646–58.Google Scholar
15
15Anderson, GF, Hussey, PS. Population aging: a comparison among industrialized countries. Health Aff2000 mai/juin;19:191–203.CrossRefGoogle ScholarPubMed
16
16Romanow, RJ. Déclaration sur la publication du rapport final de La Commission sur l'avenir des soins de santé au Canada, l'Amphithéâtre national de la presse, Ottawa, le 28 novembre, 2002. http://www.healthcare-commission.ca/ (March 5, 2003).Google Scholar